// App-Quantinova.ai

O04 : In vivo assessment of prevention of lung fibrosis using the pan-PPAR agonist lanifibranor in the TbRIIDk-fib mouse model of systemic sclerosis

Researchers

Presenter

  • Emma Derrett-Smith

Principal Investigators

  • Xu Shi-Wen

  • David Abraham

  • Olivier Lacombe

  • Pierre Broqua

  • Jean-Louis Junien

  • Irena Konstantinova

  • Christopher P Denton

Medical Centers

  • Nephrology, UCL Division of Medicine, London, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Inventiva, Inventiva, Daix, FRANCE

Locations

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Lanifibranor

  • Bleomycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved